undecanoyl carnitine | 142759-00-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: undecanoyl carnitine
• 英文别名: n-Undecanoylcarnitin；Undecanoylcarnitine；4-(trimethylazaniumyl)-3-undecanoyloxybutanoate
• CAS: 142759-00-0
• 化学式: C₁₈H₃₅NO₄
• 分子量: 329.48
• InChiKey: FPUYBGZEWPJSDX-UHFFFAOYSA-N

物化性质

• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  十一烷酸 在 氯化亚砜 作用下， 以 三氟乙酸 为溶剂， 反应 33.0h， 生成 undecanoyl carnitine
  参考文献：
  名称：

  Synthesis and preliminary evaluation of perfluoroalkylacyl carnitines as surfactants for biomedical use

  摘要：

  A series of acyl carnitines, 4 of which bearing a terminal perfluoroalkyl fragment, was obtained from carnitine in one step in a high grade of purity in yields ranging from 44-81%. The F-alkyl derivatives display high solubilities in water, strong surface activity and a significant emulsifying power towards fluorocarbons in water. In spite of their strong surface activity, all the biocompatibility tests performed (in vitro toxicity on Namalva cells cultures, hemolysis on human red blood cells, and iv injections in mice) indicate a significantly better biological tolerance than their hydrocarbon analogs, provided the F-alkyl moiety is larger than the alkyl moiety in the hydrophobic tail.

  DOI：

  10.1016/0223-5234(91)90138-d

文献信息

• Method and use of metabolites for the diagnosis and differentiation of neonatal encephalopathy
  申请人：InfanDx AG

  公开号：EP2587264A1

  公开（公告）日：2013-05-01

  The invention generally relates to the identification metabolites and signatures (panels) of metabolites, which are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. The present invention more particularly relates to an in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and / or basal ganglia.

  本发明一般涉及代谢物和代谢物特征（组）的鉴定，这些代谢物和代谢物特征可作为生物标志物用于临床诊断，特别是新生儿脑病的诊断。它们是临床鉴别诊断的有用工具，可用于早期发现脑损伤、确定受损伤影响的脑区和预测不良神经功能结果，还可用于诊断疾病进展和治疗效果。本发明尤其涉及一种体外方法，用于预测不同脑区发生新生儿脑病的可能性、确定新生儿脑病的受影响脑区以及脑损伤风险，并通过鉴定不同脑组织（尤其是海马和/或基底节）的损伤类型和程度来预测预后和神经系统结果。
• Diagnosis and treatment of neonatal encephalopathy
  申请人：InfanDx AG

  公开号：US10514383B2

  公开（公告）日：2019-12-24

  Metabolites and signatures (panels) of metabolites are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. An in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and/or basal ganglia, is provided.

  代谢物和代谢物特征（组）可作为生物标记物用于临床诊断，尤其是新生儿脑病的诊断。它们是临床鉴别诊断的有用工具，可用于早期发现脑损伤、确定受损伤影响的脑区和预测不良神经系统结果，还可用于诊断疾病进展和治疗效果。本研究提供了一种体外方法，用于预测不同脑区发生新生儿脑病的可能性、确定新生儿脑病的受影响脑区、脑损伤风险以及由于确定不同脑组织（特别是海马和/或基底节）的损伤类型和程度而导致的预后和神经系统结局。
• Method of diagnosing and treating asphyxia
  申请人：InfanDx AG

  公开号：US11313866B2

  公开（公告）日：2022-04-26

  A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.

  一种体外诊断窒息和相关疾病的方法，一种体外估计窒息患者缺氧持续时间的方法，以及一种体外监测常氧、缺氧和高氧条件和/或常压氧和高压氧治疗的方法，包括定量检测患者生物样本中多种窒息特异性内源性化合物，这些化合物选自由生物胺组成的组；氨基酸、胆汁酸、羧酸、二十酸、脂类、胆固醇前体、胆固醇代谢物、前列腺素和糖类。
• PERFLUORINATED ESTERS OF ALKANOYL L-CARNITINE FOR THE PREPARATION OF CATIONIC LIPIDS FOR THE INTRACELLULAR DELIVERY OF PHARMACOLOGICALLY ACTIVE COMPOUNDS
  申请人：SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

  公开号：EP1075461B1

  公开（公告）日：2004-07-28
• Method of diagnosing asphyxia
  申请人：InfanDx AG

  公开号：EP2249161B1

  公开（公告）日：2020-05-13